- Home
- MBRX
as 07-26-2024 4:00pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 11.4M | IPO Year: | 2016 |
| Target Price: | $35.00 | AVG Volume (30 days): | 14.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $6.24 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Moleculin Biotech Inc. (MBRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | MBRX | CEO and President | Dec 26 '23 | Buy | $0.69 | 188,404 | $129,998.76 | 680,880 | SEC Form 4 |
| George Robert E. | MBRX | Director | Dec 26 '23 | Buy | $0.69 | 14,493 | $10,000.17 | 14,660 | SEC Form 4 |
| Foster Jonathan P. | MBRX | Chief Financial Officer | Dec 26 '23 | Buy | $0.69 | 28,986 | $20,000.34 | 80,556 | SEC Form 4 |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
PR Newswire
16 days ago
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
PR Newswire
a month ago
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
PR Newswire
a month ago
Moleculin to Present at the Virtual Investor Pitch Conference
PR Newswire
2 months ago
Moleculin to Participate in the Virtual Investor Lunch Break Series
PR Newswire
2 months ago
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
Clinical Trials Arena
2 months ago
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
PR Newswire
2 months ago
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
GuruFocus.com
2 months ago
Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.